<p>Introduction</p><p>Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes</p> <p>Phil Skolnick</p> <p>Section 1. Vaccines</p> <p> </p>Therapeutic Vaccines for Treating Nicotine Addiction.<p></p> <p>Matthew W. Kalnik, Ph.D.</p> <p>Vaccines for Treating Cocaine Use Disorders </p> <p>Coreen B. Domingo; Daryl Shorter; Thomas R. Kosten </p> <p>Vaccines for Opioid Addiction</p> <p></p>Michael Raleigh and Paul Pentel<p></p> <p>Vaccines for Methamphetamine Use Disorder </p> <p>Thomas R. Kosten and Therese A. Kosten </p> <p>Vaccine for Cocaine Addiction and HIV infection</p> <p>Timothy Cardozo, Sergey Shmelkov, Kenneth Ca</p>rr, John Rotrosen, Pedro Mateu-Gelabert, Samuel R. Friedman<p></p> <p>Section 2. Monoclonal antibodies</p> <p>Monoclonal Antibodies: Introduction</p> <p>S. Michael Owens</p> <p>Anti-cocaine monoclonal antibodies</p> Hanna N. Wetzel, William J. Ball and Andrew B. Norman <p></p> <p>Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for use in Treating Methamphetamine Abuse</p> <p>Michael D. Hambuchen, Misty W. Stevens, Melinda G. Gunnell, W. Brooks Gen-try, and S. Michael Owens</p> Section 3. Enzymes<p></p> <p>Enzyme-based cocaine pharmacotherapies: Current status and projections for the future. </p> <p>James H. Woods, Chang-Guo Zhan</p> <p></p>Viral gene transfer of enzymes<p></p> <p>W. Steve Brimijoin Cocaine Hydrolases Designed from Butyrylcholinesterase </p> <p>Fang Zheng and Chang-Guo Zhan </p> Section 4. Strategies to optimize the development of biologics to treat addictions<p></p> <p>Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders</p> <p>David F. Havlicek, Jonathan B. Rosenberg, Dolan Sondhi, Ronald G. Crystal </p> <p>and Stephen M. Kaminsky</p> <p>Nanotechnology based nicotine vaccine</p> <p>Petr O. Ilyinskii and Lloyd P.M. Johnston</p> <p>Exploration of DNA nanostructures for rational design of vaccines</p> <p>Xiaowei Liu, Sidney M. H</p>echt, Hao Yan, Paul R. Pentel, and Yung Chang<p></p> <p>Adjuvants for Substance Abuse Vaccines</p> <p> Frank M. Orson, Berma M. Kinsey, Muthu Ramakrishnan, Reetakshi Arora, Thomas R. Kosten</p> <p>Skin Vaccination against Nicotine Addiction</p> <p>Xinyuan Chen, Ji Wang, Jeffrey H. Wu, and Mei X. Wu</p> <p>Hapten design for anti-addiction vaccine development</p> <p>Karen C. Collins, Kim D. Janda</p> <p>B cell mechanisms underlying vaccine efficacy against drugs of abuse</p> <p> Marco Pravetoni, Ph.D. </p>prave001@umn.edu<p></p> <p>Section 5. Practical Considerations</p> <p>Practical considerations for the development of vaccines against drugs of abuse</p> <p>Oscar B. Torres, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice and</p><p></p> Gary R. Matyas<p></p> <p>Ethical Aspects of Biologics to Treat Substance Use Disorders</p> <p>Ivan D. Montoya</p> <p> </p>
